DNA-demethylating agents activate tumor suppressor genes that are silenced by DNA methylation in cancer and are therefore emerging as a novel approach to cancer therapy. 5-azacytidine (VIDAZA), the first representative of this class of drugs was approved for treatment of myelodysplastic syndromes and is currently being tested on other cancers including solid tumors. However, 5-azacytidine or its deoxy-analog, 5-aza-2′-deoxycytidine (5-azaCdR) could also induce methylated prometastatic genes by DNA demethylation and induce cancer cell invasiveness. Since 5-azacytidine is a potent cancer growth inhibitor, we tested whether combining it with a DNA-methylating agent, the methyl donor S-adenosyl methionine (SAM), would block the adverse demethylating activity of 5-azaCdR while maintaining its growth suppression effects. We show here using several invasive and non-invasive breast cancer cell lines that SAM inhibits global-and gene-specific demethylation induced by 5-azaCdR, prevents 5-azaCdR activation of prometastatic genes uPA and MMP2, resulting in inhibition of cell invasiveness while augmenting the growth inhibitory effects of 5-azaCdR and its effects on tumor suppressor genes. Combination of drugs acting on the DNA methylation machinery at different levels is proposed as a new strategy for epigenetic therapy of cancer.
Introduction
DNA methylation enzymes are deregulated in cancers, leading to changes in epigenetic programing (1) . It has been proposed almost two decades ago that DNA methylation proteins are candidate targets for anticancer therapeutics (2) . We have shown previously that some of the nodal anticancer pathways aberrantly activate DNA methyltransferase 1 (DNMT1), the enzyme that maintains the DNA methylation pattern (3) . The main focus in the field has been on reactivation of the genes that are silenced by methylation and normally block cancer growth. DNA methylation inhibitors are emerging as a novel approach to treating cancer and the first DNA methylation inhibitor 5-azacytidine (VIDAZA) and its deoxyribose analog 5-aza-2′-deoxycytidine (5-azaCdR) have been approved for treatment of certain leukemias (4) . However, it has been known for decades that a hallmark of cancer is global hypomethylation (5) . It was originally believed that global hypomethylation mainly targets repetitive sequences (6) , but several prometastatic genes were shown previously to be hypomethylated in cancers as well (7) (8) (9) . A recent delineation of the landscape of DNA hypomethylation in liver cancer revealed several thousands of gene promoters that were hypomethylated relative to adjacent normal liver tissues (10) . The hypomethylated genes include members of functional gene pathways involved in cancer growth and metastasis (10) . These data raise the possibility that DNA methylation inhibitors would induce metastasis in non-invasive cancers. Indeed, we have shown that 5-azaCdR induces invasiveness of non-invasive breast cancer cells in vivo and in vitro (11) . This should point to a serious concern in further clinical use of DNA methylation inhibitors in treating cancer. In accordance with this hypothesis, we have shown previously that 5-azaCdR increases the invasiveness of non-invasive breast cancer cell lines in vitro and in vivo (12) (13) (14) .
We have shown that prometastatic genes uPA and MMP2 are demethylated in invasive breast cancers and that we could block the invasiveness and metastatic properties of breast cancer cells MDA-MB-231 (15, 16) and prostate cancer cells PC-3 using the methyl donor S-adenosyl methionine (SAM). SAM treatment reversed the demethylated state of these prometastatic genes (15, 16) either by providing extra methyl moieties to the DNMTs or by inhibiting DNA demethylation as we have shown previously (17) . Both of these mechanisms could result in hypermethylation upon SAM treatment.
Since DNA methylation inhibitors are also potent inhibitors of tumor growth, it is important to examine whether it is possible to block the adverse effects of these inhibitors on cell invasiveness without affecting their growth inhibitory properties. We therefore reasoned that combining SAM and 5-azaCdR might block the adverse effects of 5-azaCdR. However, it is critical to test whether the combination of SAM and 5-azaCdR would not reverse the potential therapeutic effects of 5-azaCdR on inhibition of cancer growth. In this paper, we demonstrate that combining SAM and 5-azaCdR results in synergistic anticancer effects on human breast cancer cell lines: maintaining the antigrowth activities of 5-azaCdR while reversing its proinvasive effects. As SAM is a nutritional supplement with very limited toxicity, the combination of 5-azaCdR and SAM is potentially a promising therapeutic approach to treatment of cancer.
Materials and methods

Cell culture and drug treatments
Human non-invasive breast cancer cell lines MCF-7 and ZR-75-1, and invasive breast cancer cell line MDA-MB-231 were purchased from American Type Culture Collection. MCF-7 cells were cultured in minimum Eagle's medium with 10 μg/ml of insulin (Invitrogen). ZR-75-1 cells were cultured in RPMI-1640 medium. MDA-MB-231 cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen). All media were supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin. For 5-azaCdR (Sigma) treatment, cells were grown in regular culture medium in the presence 0.05-5 μM of 5-azaCdR. SAM chloride (Sigma) were prepared in a buffer containing 0.005 M sulfuric acid and 10% ethanol. SAM (10, 50 or 100 μM) or equivalent volumes of buffer were added to regular culture medium. Media were refreshed daily over a period of 3 or 6 days. Data presented for the SAM treatment groups are deducted from the dissolution buffer background. In the case when more than one drug was used, both drugs were added simultaneously.
Boyden chamber Matrigel invasion assay
Invasion assays were carried out using the Invasion assay kit (Chemicon) following the manufacturer's protocol. After the respective drug treatments, the cells were trypsinized and counted using trypan blue exclusion assays to ensure that the same number (1.5 × 10 5 ) of viable cells was plated into the upper chambers of the Matrigel Boyden wells in serum-free media at the start of the assay. Five hundred microliters of regular culture media containing 10% fetal bovine serum was added to the lower chamber as chemoattractant. After incubation for 48 h at 37°C, the non-invaded cells that remained in the upper chambers were removed with cotton swabs. The invaded cells at the bottom of membrane were stained and counted under light microscope with ×400 magnification. Five randomly selected fields were counted and averaged.
Growth assays
The growth of cells was measured by trypan blue exclusion assays. At the end of each treatment period, the cells were trypsinized and stained with 0.4% trypan blue. Cells were placed in a hemocytometer and counted under microscope. Non-viable cells that were stained blue were excluded from counting.
Abbreviations: 5-azaCdR, 5-aza-2′-deoxycytidine; DNMT, DNA methyltransferase; SAM, S-adenosyl methionine.
Synergism of SAM and 5-aza-2′-deoxycytidine
Luminometric methylation assay Global DNA methylation was determined using luminometric methylation assay as described previously (18, 19) . Briefly, 1 μg of DNA was digested with either the methylation-sensitive enzyme HpaII (NEB) or the methylation insensitive enzyme MspI (NEB), respectively. EcoRI was added to both digestions as internal controls of DNA concentration. Digested DNA was then subjected to end filling with (either C for MspI and HpaII or A for EcoR1) using PyroMark™Q24 pyrosequencer. The percentage of methylation was determined by dividing the relative peak heights of HpaII to that of MspI after normalization of each peak with the respective EcoRI peaks using the PyroMark™Q24 (Biotage) software.
RNA extraction and quantitative real-time PCR RNA was extracted using TRIzol reagent as described previously (20) . Reverse transcription was performed using 1 μg of RNA and 20 U of reverse transcriptase (Roche) as recommended by the manufacturer. Two microliters of complementary DNA was used in a 20 μl reaction containing 1X SYBR green mix, 0.5 μM forward and 0.5 μM reverse primers. Reaction was performed in Roche LightCycler LC480 using the following conditions: denaturation 95°C for 10 min; amplification 95°C for 10 s; annealing temperature 10 s; extension 72°C for 10 s, 45 cycles; final extension 72°C for 10 min. Primer sequences for each gene are as follows: uPA (forward: 5′-TTC GGA GGG CAG CAC TGT GAA ATA-3′; reverse: 5′-GCA TGG TAC GTT TGC TGA AGG ACA-3′), MMP2 (forward: 5′-TCA TTG GCT ACA CAC CTG-3′; reverse: 5′-CGT CAA AGG GGT ATC CAT-3′), p21 (forward: 5′-TGG AGA CTC TCA GGG TCG AAA-3′; reverse: 5′-GGC GTT TGG AGT GGT AGA AAT C-3′), CDKN2AIP (forward: 5′-ATC GAG TAG CAA TGA AGG-3′; reverse: 5′-GAT GCA GCT TCT GTC TTG-3′) and 18S (forward: 5′-CAC GGG AAA CCT CAC CCG GC-3′; reverse: 5′-CGG GTG GCT GAA CGC CAC TT-3′). Quantification was performed using the second derivative method by Roche LightCycler 480 software.
Western blotting
Forty micrograms of nucleic extracts were fractionated on a 12.5% sodium dodecyl sulfate-polyacrylamide gel and transferred to nitrocellulose membrane. Non-specific binding was blocked with 5% milk in Tris-buffered saline (TBSM) for antibodies against MMP2 (Millipore MAB13405), CDKN2AIP (Abcam ab140519) or phosphate-buffered saline (PBSM) for antibodies against uPA (Santa Cruz sc-14019) and p21 (Santa Cruz sc-397). After blocking, the membrane was incubated with specific antibodies in TBSTM (TBSM with 0.05% Tween) or PBSTM (PBSM with 0.05% Tween) for 2 h followed by anti-mouse (Jackson ImmunoResearch Labs) or anti-rabbit immunoglobulin G (Sigma) and an enhanced chemiluminescence detection kit (Amersham Pharmacia Biotech). Nucleoporin p62 was used as loading control and was detected using anti-Nucleoporin p62 antibody (BD Bioscience 610498) in TBSTM followed by anti-mouse immunoglobulin G (Jackson ImmunoResearch Labs) in Tris-buffered saline with Tween 20.
Pyrosequencing
One microgram of DNA samples were subjected to bisulfite conversion as described previously (21) . The converted DNA was cleaned up using the EpiTect Bisulphite Kits (Qiagen) according to the manufacturer's protocol. For pyrosequencing, the bisulfite DNA was subjected to PCR amplification using biotinylated primers: uPA (outside forward: 5′-GTT TTT TTT AAA TTT TTG TGA G-3′, reverse: 5′-ACT ATC TCT CTC CTC TCT AAA CTC C-3′; nested forward: 5′-AGA GTT GTA AGA TAG GGG AGG GAG T-3′; nested biotinylated reverse: 5′-Biotin/CCC TAC CAA AAC AAA TAA ACC CTA AC-3′; sequencing: 5′-GGG AGG GTT TTG ATA TAG A-3′), MMP2 (outside forward: 5′-GTT TTT GAT TTT AGG GAG TGT AGG-3′, reverse: 5′-TTT ATA TAT TTA AAA CCC CAA ATA C-3′; nested forward: 5′-GTT TTT TAG TAG GGG GTT TTG AG-3′; nested biotinylated reverse: 5′-Biotin/TCC TCC ACT TTT CTC CTC TTT TTT-3′; sequencing: 5′-GAG GTA AGT GGG GTG A-3′), p21 (forward: 5′-GAT TGG GGG AGG AGG GAA-3′; biotinylated reverse: 5′-Biotin/AAC CCA AAC TCC TAA CTA CC-3′; sequencing: 5′-GGA GGG AAG TGT TTT-3′) and CDKN2AIP (forward: 5′-G AGT TGA TTA GGA GGG GGA GGA GGA-3′; biotinylated reverse: 5′-Biotin/ACT TCT TCC CTT TTA TAA CCT C-3′; sequencing: 5′-GGT GTT TTT AGT GGT TTT AAG GGG-3′). Twenty-five microliters of PCR products were used to perform pyrosequencing with 0.3 μM of sequencing primers in PyroMark™Q24 (Biotage). Data were analyzed by the PyroMark™Q24 software.
Statistics
Student's t-tests were performed to determine statistical significance of the results. Individual treatments were compared with untreated controls. In addition, we compared results obtained for 5-azaCdR and 5-azaCdR plus SAM. Significance threshold was set at P value <0.05 and indicated by asterisks (*).
Results
SAM reverses 5-azaCdR-induced invasion and synergizes growth suppression in MCF-7 cells
SAM is a methyl donor and an inhibitor of DNA demethylation (17) . We therefore tested whether SAM could suppress cell invasiveness induced by 5-azaCdR. We first performed dose-dependent experiments in non-invasive human breast cancer cell line MCF-7 with 5-azaCdR ( Figure 1A) . The low 5-azaCdR concentration of 0.3 μM was chosen for future studies with SAM since it caused highest cell invasion while minimally affecting growth ( Figure 1A) . We then asked whether SAM could counteract the proinvasive activity of 5-azaCdR. We used inhibition of the expression of uPA, a protein that we and others have shown is induced by 5-azaCdR (11, 12) and determines cell invasiveness, to define the concentration of SAM that has maximal effect on 5-azaCdR activity ( Figure 1B) . The concentrations of 100 μM SAM and 0.3 μM 5-azaCdR were used for the rest of the study. We also addressed the question of whether SAM has independent effects on cell growth in the concentrations that we have used here. We measured the effects of increasing concentrations of SAM on growth independently (no significant effects) and in the presence of 5-azaCdR where it augments the growth suppression effects of 5-azaCdR ( Figure 1C ). Using Matrigel Boyden chamber invasion assays, we observed minimal background for the non-invasive MCF-7 cells as well as the SAM-treated cells ( Figure 1D ). Consistent with our previous study, 5-azaCdR increased the invasiveness of the cells. Interestingly, a combination of 5-azaCdR and SAM significantly reversed 5-azaCdR-induced invasion ( Figure 1D ). These results show that a combination of 5-azaCdR and SAM could be therapeutically beneficial by synergizing reduced cancer cell growth with reduced risk of metastasis.
SAM inhibits the global hypomethylation induced by 5-azaCdR
To test whether the mechanism of action of SAM involves inhibition of demethylation, we determined whether it would block the global hypomethylation induced by 5-azaCdR. Global hypomethylation is a hallmark of cancer and we reasoned that it would be important to reverse this adverse effect. Global demethylation has been associated with genomic instability, which increases the risks of genetic mutations and chromosomal rearrangements (22, 23) . Interestingly, SAM alone did not further increase the global state of methylation of MCF-7 cells, as determined by luminometric methylation assays ( Figure 1E ). 5-azaCdR treatment, as expected, caused massive global demethylation. However, SAM treatment resulted in a sizable and significant inhibition of the global demethylation triggered by 5-azaCdR alone ( Figure 1E ). The fact that the global methylation pattern was significantly inhibited by the combination of 5-azaCdR and SAM could be due to DNA methylation activity. However, it is known that 5-azaCdR inhibits all DNMTs at the protein level and therefore DNA methylation activity in the presence of 5-azaCdR should be extremely limited and might account only for part of the mechanism. Alternatively, the data is consistent with the hypothesis that part of the mechanism of action of SAM involves inhibition of DNA demethylation (17) .
SAM inhibits the induction of prometastatic genes by 5-azaCdR but does not inhibit the induction of tumor suppressor genes
To determine whether the mechanism of action of SAM involves inhibition of 5-azaCdR-triggered induction of prometastatic genes, we determined whether co-treatment with SAM and 5-azaCdR will inhibit the induction of two prometastatic genes urokinase plasminogen activator (uPA) and matrix metallopeptidase 2 (MMP2) that we have shown previously to be induced by 5-azaCdR in MCF-7 cells (12, (24) (25) (26) (27) (28) . Both genes (uPA and MMP2) were induced as expected by 5-azaCdR, whereas addition of SAM inhibited their induction (Figure 2A and C) . One concern in combining DNA-methylating and -demethylating agents is that the methylating agents will antagonize the beneficial as well as the adverse effects of the demethylating agent. We therefore measured the impact of SAM on the expression of two representative tumor suppressor genes p21 and CDKN2AIP.
Both of these genes encode proteins that are important in the control of cell cycle progression as well as the p53 pathway, which are often dysregulated in cancer (29) . These genes have also been shown to play a major role in the antiproliferative effects of 5-azaCdR (30) . Interestingly, SAM affected the prometastatic genes and the tumor suppressor genes differently. SAM did not inhibit induction of CDKN2AIP by 5-azaCdR, whereas p21 was induced to a higher level when both agents were combined ( Figure 2B and C) . These data illustrate that SAM is selective in inhibiting prometastatic genes and does not affect tumor suppressor genes, which could explain its synergistic growth inhibitory effect with 5-azaCdR.
SAM inhibits hypomethylation by 5-azaCdR in prometastatic genes but not in tumor suppressor genes
To determine whether the mechanism of action by which SAM silences prometastatic genes (Figure 2A ) involves inhibition of hypomethylation induced by 5-azaCdR, we analyzed by bisulfite conversion and pyrosequencing the state of methylation of CpG sites in the promoters of uPA and MMP2 genes. These two prometastatic genes are poorly expressed (Figure 2A ) and heavily methylated in several CpG sites in uPA promoter (sites 6 and 8) and the MMP2 promoter (sites 1-5; Figure 3A ). While SAM treatment alone did not cause further hypermethylation of either gene, 5-azaCdR caused hypomethylation in almost all CpG sites studied ( Figure 3A ). In the uPA promoter, addition of SAM to the 5-azaCdR treatment suppressed 5-azaCdRinduced hypomethylation and reversed DNA methylation back to the control levels, or to a more hypermethylated state at almost all measured CpG sites ( Figure 3A) . The effect of SAM in the MMP2 promoter was highly selective and a complete reversal of hypomethylated state was observed in CpG site number 4 ( Figure 3A) . To understand the basis for the selectivity of SAM, we examined the state of methylation of promoters of the tumor suppressor genes p21 and CDKN2AIP ( Figure 3B ). Interestingly, in both cases, the promoters are unmethylated in control cells but nevertheless 5-azaCdR induces their expression ( Figure 2B ). Previous studies have shown that p21 promoter is unmethylated in most cancer cell lines and that 5-azaCdR could induce tumor suppressor genes expression through methylation-independent mechanisms (31,32). Remarkably, SAM does not trigger methylation were subjected to trypan blue exclusion assays at the end of the treatment period. The graph shows the percentage of growth relative to untreated MCF-7 cells ± standard error of the mean from triplicate experiments (*P < 0.05, two-tailed Student's t-test). (D) MCF-7 cells were treated with 100 μM SAM and 0.3 μM 5-azaCdR, alone or in combination, for 72 h. Boyden chamber invasion assays were performed on treated cells as described in Materials and methods. The graph shows the average number of invaded cells per field calculated from five randomly selected fields under ×400 magnification (*P < 0.05, two-tailed Student's t-test). (E) SAM reverses 5-azaCdR-induced global demethylation. DNA was extracted from MCF-7 cells treated with 100 μM SAM and 0.3 μM 5-azaCdR, alone or in combination, for 72 h as described in Materials and methods. DNA (1 μg) from each sample was subjected to methylation-sensitive enzymes HpaII and MspI control digestion, respectively, at 37°C for 4 h. EcoRI was included in both reactions to normalize the total amount of DNA. Luminometric methylation assays were performed in PyroMark™Q24 (Biotage). Data were analyzed using PyroMark™Q24 software to determine the genomic DNA methylation level (% methylation = (1 − ratio of HpaII/EcoRI to MsPI/EcoRI) × 100%). The graph represents average methylation percentage ± standard error of the mean from three independent experiments (*P < 0.05, two-tailed Student's t-test).
of these genes, which explains why SAM does not silence their expression. SAM on its own is a methyl donor, which does not possess catalytic activity. DNMTs interaction with the promoters is required for methylation. The fact that these tumor suppressor genes are unmethylated in MCF-7 cells indicates that they are poor substrates of DNMTs in these cells and therefore remain unmethylated even upon addition of SAM. An alternative mechanism is that SAM inhibits active demethylation in the presence of 5-azaCdR. As these genes are unmethylated in untreated cell, inhibition of demethylation should have no effect.
SAM inhibits 5-azaCdR-triggered activation of uPA and invasiveness and augments its antigrowth effects in different human breast cancer cell lines
To exclude the possibility that the effect of SAM is an idiosyncrasy of the MCF-7 cell line, we tested whether similar effects will be seen in other breast cancer cell lines. We repeated our treatments in non-invasive human breast cancer cells ZR-75-1 and the highly invasive breast cancer cells MDA-MB-231. ZR-75-1 cells has previously been shown to increase invasiveness upon 5-azaCdR treatment. Our short term, low-dose 5-azaCdR treatment also induced invasion in this cell line ( Figure 4A ). Expression of uPA increases in response to 5-azaCdR in ZR-75-1 cells and this induction of uPA messenger RNA levels is suppressed when SAM is added ( Figure 4B ). SAM inhibits growth on its own and it augments the antigrowth of 5-azaCdR beyond the effect seen when 5-azaCdR is administered on its own ( Figure 4C ).
Human breast cancer line MDA-MB-231 cells are highly invasive where uPA and other prometastatic genes are unmethylated (15) . In these cells, 5-azaCdR inhibits rather than increase metastasis. SAM inhibits invasiveness on its own as we previously reported (12, 15, 16) and it adds on the anti-invasive effect of 5-azaCdR when added to 5-azaCdR ( Figure 5A ). uPA levels are high in these invasive cells in the absence of 5-azaCdR, presence of 5-azaCdR did not lead to further induction of uPA, whereas SAM alone or in combination with 5-azaCdR significantly suppressed uPA expression ( Figure 5B ). 5-azaCdR inhibits growth of MDA-MB-231 cells, which is not affected by SAM. Thus, although 5-azaCdR has a different impact on invasive and non-invasive breast cancer cells, SAM inhibits prometastatic genes and invasiveness in both cell types when added to 5-azaCdR without compromising the antigrowth effects ( Figure 5C ).
Discussion
DNA-demethylating agents are promising anticancer agents. These agents were shown to demethylate and induce the expression of tumor suppressor genes and display strong anticancer growth effect in vitro (33) , in vivo and in the clinic (34) . However, there is significant Fig. 3 . SAM reverses hypomethylation of prometastatic genes uPA and MMP2 triggered by 5-azaCdR treatment. DNA isolated from MCF-7 cells treated with either 100 μM SAM and/or 0.3 μM 5-azaCdR for 72 h was subjected to sodium bisulfite conversion as described in Materials and methods. Bisulfite-converted DNA samples were used as templates for PCR using biotinylated 5′ primers. The PCR product for (A) uPA and MMP2 and (B) p21 and CDKN2AIP genes was used for pyrosequencing using PyroMark™Q24 (Biotage). Graphs represent mean percentage methylation ± standard error of the mean at each CpG site from triplicate experiments (*P < 0.05, two-tailed Student's t-test). A schematic diagram is shown for each sequenced region with gray bars indicating cytosine guanine areas (straight lines). evidence that the DNA methylation changes in cancer are not only limited to increased methylation but also includes a broad landscape of demethylated gene promoters (10) . More importantly, the demethylated genes play an important role in migration and invasion. These functions are required for cancer metastasis, one of the most morbid aspects of cancer (10) . This points to the possibility that DNAdemethylating agents such as 5-azaCdR could have adverse effects of increasing metastasis, which contraindicates their clinical utility.
The complexity of DNA methylation effects in cancer implies that single therapy targeting of DNA methylation enzymes would be inadequate, particularly since the changes in DNA methylation are complex and involve both increase and decrease in DNA methylation. A combination therapy that targets several aberrant processes in cancer might be required. We tested here the possibility that the adverse effects of DNA demethylation might be addressed by combining a DNA-demethylating agent with a DNA-methylating agent. Such a combinatorial anticancer therapy would be successful only if the methylating agent exhibits certain selectivity to prometastatic genes and reduced affinity to tumor suppressor genes. SAM is an attractive molecule to be combined with DNA-demethylating agents since it has been shown previously to suppress both growth and invasion in highly invasive cell lines (15, 16) . In addition, it is a natural compound that is a cofactor of methylation reactions in vivo. It is synthesized in humans from the methyl donors in diet and requires the availability of common vitamins such as vitamin B12 and folic acid (35) . We therefore tested here first whether SAM will antagonize the prometastatic effects of 5-azaCdR, and second whether SAM would exert the same growth suppression effects in the presence of 5-azaCdR. We demonstrate here that SAM antagonizes the effects of 5-azaCdR on cell invasiveness ( Figure 1B and D) and augments the antigrowth effects of 5-azaCdR ( Figure 1C) . SAM inhibits the global hypomethylation induced by 5-azaCdR ( Figure 1E ), suggesting that a component of its mechanism of action involves blocking partially the DNA demethylation induced by 5-azaCdR. SAM mechanism of action is selective since it blocks the induction of prometastatic genes by 5-azaCdR (Figure 2A ) but does not inhibit tumor suppressor genes ( Figure 2B ). SAM as well as 5-azaCdR affects gene expression by methylationdependent and -independent mechanisms. The silencing of uPA ( Figure 3A) and MMP2 ( Figure 3B ) is associated with methylation of CpG sites in the promoter in a site-selective manner. However, SAM is a ubiquitous methyl donor that is required for histone and protein methylation, which could impact gene expression independent of DNA methylation. Although 5-azaCdR is an inhibitor of DNA methylation, the tumor suppressor gene p21 is induced by 5-azaCdR by a DNA methylation-independent mechanism that involves changes in histone modifications and upstream effectors (32,36) Interestingly, SAM treatment alone does not increase methylation compared with control cells but only inhibits demethylation that is induced by the demethylating agent 5-azaCdR ( Figures 1E and 3) . This supports the conclusion that elevated SAM should not affect normal processes nor increase methylation in genes that are not affected by 5-azaCdR. It also supports the hypothesis that SAM inhibits DNA demethylation in these breast cancer cell lines as has been previously suggested (17) rather than increasing methylation. The current study is limited to several examples of prometastatic and tumor suppressor genes. Future experiments along this line should include a more global view on the gene expression changes upon treatment with SAM.
The effect of SAM in inhibiting invasiveness and expression of uPA is also seen in a different non-invasive human breast cancer line ZR-75-1 ( Figure 4A and B) . Similar to the situation in MCF-7 cells, SAM augments 5-azaCdR inhibitory effects on cell growth ( Figure 4C ). We also measured the effects of SAM on 5-azaCdRtreated invasive human breast cancer cell line MDA-MB-231. Tumors naturally include invasive and non-invasive cells and it is therefore important to rule out adverse effects on these cells. SAM treatment alone has a growth inhibitory effect in these cells ( Figure 5C ), and it does not inhibit the growth inhibitory effect of 5-azaCdR. Interestingly, 5-azaCdR has opposite effects on invasion in invasive ( Figure 5 ) and non-invasive (Figures 1 and 4 ) breast cancer cells. This could be explained by the different epigenetic matrix that 5-azaCdR is acting on in both cell types. In the non-invasive cells MCF-7 and ZR-75-1, 5-azaCdR induces prometastatic genes that are silenced by hypermethylation, thus leading to increased metastasis. In invasive MDA-MB-231 cells, the prometastatic genes uPA and MMP2 are hypomethylated as we have shown previously (12, 15) . 5-azaCdR is not expected to have any further effects on these genes. However, 5-azaCdR might be inducing metastasis inhibitory genes such as TIMP3 and SKY (37, 38) , which display promoter hypermethylation only in invasive phenotypes. Our data demonstrate that combining SAM with 5-azaCdR will inhibit the induced adverse invasiveness by 5-azaCdR without affecting its beneficial effects on growth in either invasive or non-invasive breast cancer cells. The differences in response to 5-azaCdR between invasive and non-invasive breast cancer cells have general implications for the general utility of epigenetic drugs in cancer therapy and other diseases as well. The consequences of epigenetic drug treatment will be different based on the cellular context and the epigenetic 'history' of the cells. This should add high cell selectivity to inherently non-selective drugs.
In summary, our data point to new therapeutic potential of combinations of epigenetic drugs that target different elements of the aberrant DNA methylation state in cancer. Our data suggest that with the appropriate combination it might be possible to block the adverse molecular effects of DNA-demethylating agents while maintaining their clinical benefits. Combining 5-azaCdR or other demethylating agents with SAM is especially attractive since SAM is a nutritional supplement that has been widely used in the population. Future experiments should test this possibility in vivo using additional cancer models.
Funding
Canadian Institute of Health Research (MOP-42411 to M.S.).
